Eloralintide + Placebo
Phase 3Recruiting 0 views this week 0 watching⚡ Active
Interest: 47/100
47
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Sleep Apnea, Obstructive
Conditions
Sleep Apnea, Obstructive, Obesity, Overweight
Trial Timeline
Feb 10, 2026 → Apr 1, 2028
NCT ID
NCT07369011About Eloralintide + Placebo
Eloralintide + Placebo is a phase 3 stage product being developed by Eli Lilly for Sleep Apnea, Obstructive. The current trial status is recruiting. This product is registered under clinical trial identifier NCT07369011. Target conditions include Sleep Apnea, Obstructive, Obesity, Overweight.
What happened to similar drugs?
20 of 20 similar drugs in Sleep Apnea, Obstructive were approved
Approved (20) Terminated (2) Active (0)
Hype Score Breakdown
Clinical
17
Activity
15
Company
15
Novelty
0
Community
0
Clinical Trials (6)
| NCT ID | Phase | Status |
|---|---|---|
| NCT07369011 | Phase 3 | Recruiting |
| NCT07392190 | Phase 3 | Recruiting |
| NCT07353931 | Phase 3 | Recruiting |
| NCT07321886 | Phase 3 | Recruiting |
| NCT07282600 | Phase 3 | Recruiting |
| NCT06916091 | Phase 1 | Completed |
Competing Products
20 competing products in Sleep Apnea, Obstructive